crta
Hrvatska znanstvena Sekcija img
bibliografija
3 gif
 Naslovna
 O projektu
 FAQ
 Kontakt
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Upute
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 779870

Zbornik radova

Autori: Mikolašević, Ivana; Orlić, Lidija; Milić, Sandra; Lukenda Žanko, Vesna; Rački, Sanjin; Štimac, Davor
Naslov: NONALCOHOLIC FATTY LIVER DISEASE AND THE RENIN-ANGIOTENSIN SYSTEM BLOCKERS
Izvornik: Knjiga sažetaka 7. kongresa Hrvatskog gastroenterološkog društva
Skup: 7.kongres Hrvatskog gastroenterološkog društva
Mjesto i datum: Opatija, Hrvatska, 1.-4. listopada, 2015.
Ključne riječi: nonalcoholic fatty liver disease; RAAS inhibitors
Sažetak:
AIM: Recent data suggest that the renin-angiotensin-aldosteron system (RAAS) may be of importance in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). We were interested to investigate whether the therapy with RAAS blockers in patients with different stages of chronic kidney disease (CKD) has any effect on steatosis and fibrosis grade ; NAFLD documented by transient elastography (TE) (Fibroscan®-CAP). METHODS: Of 191 patients with various stages of CKD there were 61 patients with CKD grade III and IV, 62 patients with end-stage renal disease treated with chronic hemodialysis and 68 renal transplant recipients. Liver stiffness was selected as the parameter to quantify liver fibrosis. Furthermore, the Controlled Attenuation Parameter (CAP) was used to detect and quantify liver steatosis with the help of TE. RESULTS: CKD patients (p=0.005) and CKD-NAFLD patients (p=0.0005) with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs) had statistically significant lower degree of liver stiffness in comparison to those without these medications (p = 0.005). Also, we were interested to explore is there any difference in fibrosis and steatosis grade due to use of ACE-I or ARBs. We did not find statistically significant differences between those two subgroups of patients with respect to liver steatosis/fibrosis. CONCLUSION: Based on our results, RAAS blockers could be an attractive option for the management of NAFLD. In further prospective analysis, we believe that by using TE as noninvasive method we could investigate are ACE-I/ARBs really effective medications for the treatment of NAFLD in CKD patients.
Vrsta sudjelovanja: Poster
Vrsta prezentacije u zborniku: Sažetak
Vrsta recenzije: Domaća recenzija
Izvorni jezik: ENG
Kategorija: Ostalo
Znanstvena područja:
Kliničke medicinske znanosti
Upisao u CROSBI: Sanjin Rački (sanjin.racki@uniri.hr), 5. Lis. 2015. u 11:12 sati



Verzija za printanje   za tiskati


upomoc
foot_4